Competing interests
RL and H Lode acted as consultants for Apeiron and EUSA Pharma for the clinical development of dinutuximab beta. H Lode participated in advisory boards organized by EUSA Pharma. H Loibner was CEO of Apeiron until July 2018. The remaining authors declare no competing interests.